Prof. Li received his Medical Doctorate in 2005 as an outstanding graduate of the Chinese Union Medical University (CUMU). In the same year, he worked in the Department of Thoracic Surgery at the Cancer Hospital of the Chinese Academy of Medical Sciences, where he served as an attending physician, deputy chief physician, and was appointed Chief Physician in 2019. He has a solid theoretical foundation and excellent research ability, and has accumulated rich clinical experience during my work. In 2017, he took over as the Director of the Office of Drug Clinical Trial Research Center, and his outstanding achievements in the management of clinical trial institutions and clinical and translational research, and is currently served as the chief expert of China GCP platform and Leading PI of international multicenter clinical trials of anti-cancer drug discovery. He is committed to new anti-tumor drug research, real-world research, full chain translation research of clinical trials, precision treatment of rare tumors and tumor big data research. His H-Index is 44 based on Web of Science. As a sub-project leader of the National 973 Major Project, the National Key R&D Program for Precision Medicine, the National Natural Science Foundation of China, the GCP platform leader, and the leader of the 13th and 14th Five-Year Innovation Project, he has undertaken many research projects.
Professor in Bioinformatics, Biology Department, Miami University, Ohio, USA
Dr. Dongliang Liu is a Postdoctoral Associate in the Department of Surgery at the Baylor College of Medicine. His research interests include: Cancer therapy, especially for pancreatic cancer immunotherapy; Chimeric virus-like particles (VLP) vaccine, especially for cancer vaccines; Novel antibiotics development including antimicrobial peptides; Epitomics and multi-epitope peptide vaccine development for pathogenic viruses.
I am an Assistant professor at Department of Biochemistry, State University of New York at Buffalo. I have expertise and extensive experience with developing and applying computational approaches for transcriptional and epigenetics regulation studies. As a postdoctoral fellow at Dana-Farber Cancer Institute, I developed widely used open-source algorithms, including MACS (cited over 3,200 times according to Google Scholar) to analyze ChIP-seq data, and an integrative platform for comprehensive analyses on cis-regulatory elements (http://cistrome.org/ap), which has over 3,000 users. I was a member of the Data Analysis Center and Analysis Working Group of the ENCODE and modENCODE consortium and was involved in deciphering functional elements through analyzing high-throughput profiles of chromatin factors and in comparing chromatin features between fly, worm and human genome. I have actively participated in the development of ChIP-seq guidelines for the broad scientific communities. My laboratory at University at Buffalo is focused on studying transcriptional and epigenetic regulatory mechanisms, and the influence of the genetic variations at regulatory elements.
Dr. Nguyen Esmeralda López-Lozano is a microbial ecologist who earned her doctorate in Biomedical Sciences from the Universidad Nacional Autónoma de México (UNAM). She has extensive research experience in microbial diversity and ecosystem processes, mainly focusing on biogeochemical cycles in desert soils.
Since 2014, Dr. López-Lozano has been a CONACyT professor in the Environmental Sciences Division at the Potosi Institute of Scientific and Technological Research. Her research focuses on plant microbiomes in arid environments and the role of microorganisms as bioindicators of ecosystem health. She investigates how both biotic and abiotic factors shape microbial communities and utilizes microbial parameters to assess environmental stress. In recent years, her work has also explored how microbiome insights can be applied to restoration and conservation efforts in arid regions.
Dr. Stefano Lorenzetti is a Senior Scientist within the Department of Food Safety, Nutrition and Veterinary Public Health at the Italian National Institute of Health.
His current main interests are on the development of both in vitro tools and functional biomarkers to screen the endocrine disrupting effects of environmental and dietary contaminants.
Institute of Parasitology, Czech Academy of Sciences (P.I.); Professor at the Faculty of Sciences, University of South Bohemia, Ceske Budejovice, Czech Republic; Senior Fellow of the Canadian Institute for Advanced research, Toronto, Canada.
Primary interest is functional analysis of selected mitochondrial proteins of the kinetoplastid Trypanosoma brucei.
Associate Professor at the Medical University of Innsbruck, Austria. Our work includes the study of chromatin modulating factors in Drosophila and mouse and the analysis of posttranscriptional modifications on RNA.
Research Asst. Professor, Marine Sciences, Univ. of North Carolina - Chapel Hill (2003-2017); Postdoctoral fellow, MPI – Marine Microbiology, Bremen, Germany (2000-2003); Research assistant and postdoctoral associate, Civil Engineering Dept., Northwestern University, Evanston, Ill. (1994-1999); PhD, Bacteriology, University of Wisconsin - Madison (1994); BS (1984) and MS (1986), Biology and Marine Microbiology, University of Massachusetts - Boston.
Research projects include: new methods to directly link species identity with carbon source utilization; direct profiling of microbial communities without PCR; direct detection of microbial enzymes in environmental samples.
Emiliano Maiani earned his MS and PhD in Molecular and Cellular Biology at the University of Rome “Tor Vergata”, Rome, Italy. In 2013, he joined the Cell Stress and Survival laboratory headed by prof. Francesco Cecconi at the Danish Cancer Society Research Center (DCRC), Copenhagen, Denmark. At the end of 2017, he moved for a second postdoc at the Computational Biology Laboratory headed by Elena Papaleo at the DCRC, Copenhagen. In this period, he expanded his knowledge to computational and structural biology. His research is focused on cancer biology and in particular in autophagy and DNA damage response pathways.